Phase 3 trials
Coverage of Phase 3 trials in the Nexus archive.
- STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials
GSK CEO Luke Miels announced a three-year cost-cutting plan targeting 1.9 billion pounds in annual savings by 2029, with funds reinvested into late-stage drug trials. The company aims to increase Phase 3 trials from 10 to 20 this year, focusing on areas like oncology, liver disease, vaccines, and HIV.
- STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
The U.S. experienced 227 active medication shortages in Q2 2026, with 48% being sole-source products and 10% involving life-saving contrast agents. GSK abandoned development of camlipixant, a chronic cough drug acquired for $2 billion, after Phase 3 trials showed limited efficacy.
- STAT+: Experimental hepatitis B treatment was a ‘functional cure’ for nearly 1 in 5, new data show
An experimental hepatitis B treatment, GSK’s bepirovirsen, achieved functional cures in 20% and 19% of patients in Phase 3 trials, significantly outperforming current treatments that achieve 1-3% success rates. The drug showed no functional cures in placebo groups, offering hope for a more effective solution to a disease affecting 250-300 million people globally.